Led · Equity · Jul 2026

Hongqing Technology describes itself as an integrated satellite constellation solution provider offering systematic full-chain services for low-Earth orbit projects. Founded in 2017 and headquartered in Beijing E-Town’s aerospace district, the company produces flat-panel stackable satellites and operates a Shanghai testing and development base and an Xiong’an intelligent satellite manufacturing base. It has in-house subsystems such as the Jinwu-200 krypton Hall thruster and has flown test satellites on Landspace rockets. Hongqing filed the Honghu-3 constellation with the ITU in May 2024, proposing 10,000 satellites across 160 planes, and aims to produce between 100–500 satellites annually by 2026. The company is majority-owned by Landspace and, following the latest financing, has raised over ¥2.5 billion to date to support operations, R&D and team expansion.

Participated · Series C · Feb 2026

Founded in 2022, Windrose Technology focuses on “zero-carbon long-haul smart transportation” by producing large electric trucks such as its flagship Global E700, which carries a 700 kWh battery enabling a 670 km range at 49-ton gross weight and supports megawatt-level fast charging that adds 400 km in 35 minutes. The company has already obtained vehicle certifications in China, the United States, and Europe, and has begun large-scale deliveries to key Chinese customers while targeting major roll-outs in Europe, North America, and the Asia-Pacific by 2026. Its customer list includes Decathlon, Rémy Cointreau, Nestlé, and Kühne + Nagel, among others. Windrose operates a global headquarters in Antwerp, Belgium and is building assembly facilities in Belgium, France, and the United States, complemented by renewable-energy-powered charging infrastructure. A second-generation truck with an 800 km+ range is under development to extend the firm’s technological lead. Although current revenue figures were not disclosed, the company notes successful endurance tests in harsh environments ranging from the Chilean Andes to Australian grades and U.S. comparative trials against Tesla and Volvo trucks. Management is also considering future public listings in the U.S. and Europe.

Participated · Debt Financing · Dec 2025

HemaCell develops cell therapeutics centered on the platelet lineage, with a flagship product described as the world's first megakaryocyte injection and a pipeline of platelet injection candidates. The company aims to address blood supply shortages and reduce adverse consequences associated with blood transfusions, while pursuing platelet-derived therapeutics for aging-related indications. HemaCell is advancing multiple clinical trials for its lead program and plans to use recent Series B proceeds to support those trials and pipeline development. Management has signaled plans for a pre-IPO fundraising within the year to build manufacturing bases and expand production capacity. Founder Zhu Fangfang stated the company will continue steady, market- and clinic-driven development and rapidly pursue capital market milestones to enable eventual product launches.

Participated · Equity · Mar 2024

PATEO focuses on developing next‑generation intelligent integrated domain control products, including smart cockpits, autonomous‑driving domain controllers, automotive‑grade chips, high‑performance central computing platforms (CCP) and display modules. The company plans to invest proceeds in full‑stack technological innovation, cabin‑driving fusion solutions and building an integrated smart manufacturing and supply chain system across the Yangtze River Delta with Shanghai as its axis, plus planning for a future Lighthouse Factory. It recently secured approximately ¥1.5 billion in new equity financing and signed a ¥19 billion credit and strategic cooperation agreement with seven state‑owned banks. PATEO has invested nearly ¥2 billion in R&D to date and has accumulated 6,692 intellectual property rights, 83% of which are invention patents, ranking first in China’s intelligent automotive connectivity patents. The article notes the company has completed multiple prior equity rounds and attracted strategic investors and industry partners as it expands internationally and wins overseas orders.

Led · Series B · Oct 2023

Saihe Medical develops pan-vascular active interventional products including a coronary intravascular lithotripsy system, peripheral intravascular lithotripsy system, intracardiac ultrasound imaging system and intravascular ultrasound. Founded in April 2020 and headquartered in Shenzhen, the company says it has overcome overseas high-end medical device technical barriers and independently developed these innovative products. Saihe plans to form a 4–6 product matrix by the end of 2024 and offer integrated solutions across coronary, peripheral, structural heart disease and electrophysiology indications. The company intends to simplify procedures, improve surgical efficiency and reduce medical costs to deliver safer, more accessible care. Saihe is moving toward product commercialization and is accelerating market launches to reach more patients. It is also pursuing global patents and planning overseas registration clinical programs.